Skip to Main Content

Paper Details

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Neuro Oncol
151
2023
Glioblastoma, MGMT Promoter, MGMT promoter, NIVO, Patients, TMZ, Temozolomide, glioblastoma, nivolumab, patients, temozolomide, tumors
Author NameAffiliation
Ahmed IdbaihSorbonne Universite, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hopital Universitaire La Pitie Salpetriere
Timothy F CloughesyUniversity of California los angeles
Timothy F CloughesyUniversity of California los angeles
Ashley L SumrallLevine Cancer Institute
Ghazaleh TabatabaiHertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center Tubingen-Stuttgart, University Hospital Tuebingen, Eberhard Karls University
Nicholas ButowskiUniversity of California san francisco
Nicholas ButowskiUniversity of California san francisco
Michael WellerUniversity Hospital and University of Zurich
  • 1 - 8

Datasets

Release 1.2